男友太凶猛1v1高h,大地资源在线资源免费观看 ,人妻少妇精品视频二区,极度sm残忍bdsm变态

Global EditionASIA 中文雙語Fran?ais
China
Home / China / Health

Study finds virus antibodies last at least 12 months

By WANG XIAOYU | CHINA DAILY | Updated: 2021-07-08 09:27
Share
Share - WeChat
A recovering pneumonia patient gives a thumbs-up to medical workers at Wuhan University's Zhongnan Hospital, in early 2020. [GAO XIANG/FOR CHINA DAILY]

Antibodies against the novel coronavirus can last for at least 12 months in more than 70 percent of recovered COVID-19 patients, a study published by Chinese researchers on Tuesday shows.

The finding adds to growing evidence that vaccination, which elicits an immune response in a way similar to how a live virus triggers human bodies to generate antibodies, can "effectively restrict the spread of SARS-CoV-2", the study said.

The study, published online by Nature Communications, was conducted by China National Biotech Group, a Sinopharm subsidiary, and the National Research Center for Translational Medicine at Shanghai Jiao Tong University.

Researchers collected 1,782 convalescent plasma samples from 869 recovered COVID-19 patients in Wuhan, Hubei province, within 12 months of diagnosis, and tested them for the presence and amount of RBDIgG, a type of antibody that indicates the strength of immunity against the virus.

Testing results showed that in nine months, levels of the antibody dropped to 64.3 percent of the initial level when they contracted the virus, and then stabilized into the 12th month.

"It shows that once immune responses against the novel coronavirus are induced in human bodies, antibody levels can be maintained for quite a long time," China National Biotech Group said in an article on its WeChat account on Wednesday.

The study found that the antibody response was significantly stronger in male participants than in their female counterparts in the early stages of infection, but the difference dwindled over time and nearly disappeared in 12 months.

Among participants aged 18 to 55, the older ones developed higher antibody levels, it added.

The company said the study is the longest-running research aimed at examining the persistence of antibody response in recovered COVID-19 patients.

The finding was published as mass vaccination in China proceeds smoothly, with the country stepping up vaccine donations or sales overseas.

As of Tuesday, about 1.3 billion doses of vaccines had been administered nationwide, the National Health Commission said on Wednesday.

China National Biotech Group added that the study will help improve understanding of the immunological memory elicited by the virus, and provide guidance on future research into vaccine-induced immunity and future vaccination policies in China and abroad.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
主站蜘蛛池模板: 胶州市| 昆明市| 漳平市| 鹤庆县| 乐亭县| 太康县| 龙口市| 博爱县| 麟游县| 葵青区| 枣庄市| 内江市| 天柱县| 错那县| 武邑县| 辉南县| 彰武县| 当阳市| 龙口市| 东辽县| 古交市| 丁青县| 宁明县| 崇左市| 乌拉特中旗| 团风县| 利津县| 武邑县| 宣威市| 上栗县| 清水河县| 依安县| 永春县| 五常市| 沧源| 会理县| 祁门县| 通化县| 阿瓦提县| 镇雄县| 监利县|